STOCK TITAN
  1. Home
  2. Sec-filings
  3. IPHA
  4. [6-K] Innate Pharma SA Current Report (Foreign Issuer)

Innate Pharma (Nasdaq: IPHA) schedules 2026 AGM and lab tour

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Innate Pharma S.A. will hold its Annual General Meeting of shareholders at 10:30 a.m. CEST on May 21, 2026, at its headquarters in Marseille, France. The notice, agenda, proposed resolutions, and voting instructions were published in the French legal bulletin and are available on the company’s investor website.

The AGM will be broadcast live online, and a guided tour of the company’s laboratories will be organized the same day at 9:15 a.m. CEST for shareholders who register in advance. Only shareholders with shares recorded in an account at least five trading days before the meeting, and bearer shareholders providing a broker certificate, will be entitled to participate and vote.

Positive

  • None.

Negative

  • None.
AGM date and time May 21, 2026, 10:30 a.m. CEST Annual General Meeting of shareholders at headquarters in Marseille
Share registration cutoff May 14, 2026, 00:00 (Paris time) Latest time shares must be recorded to attend and vote
Written questions deadline May 15, 2026 Final date for shareholders to submit written questions for AGM
Lab tour time May 21, 2026, 9:15 a.m. CEST Guided tour of Innate Pharma laboratories for shareholders
Notice publication date April 13, 2026 AGM notice published in BALO with agenda and resolutions
Annual General Meeting financial
"will hold its Annual General Meeting of shareholders (“AGM”) at 10:30 a.m."
au porteur financial
"Shareholders holding “au porteur” (bearer) shares will need to obtain"
Au porteur describes a financial instrument, such as a bond or share certificate, that is owned by whoever physically holds it rather than by a named owner; possession is proof of ownership much like holding a cash bill. It matters to investors because these instruments are easy to transfer—like handing over cash—but also risky, since loss or theft means loss of ownership, and they are often restricted or phased out due to legal and anti‑money‑laundering concerns.
attestation de participation financial
"will need to obtain an “attestation de participation” (certificate of shareholding)"
A attestation de participation is a short, official document from a broker, bank, or transfer agent that proves an investor held or locked up a specific security at the time needed to take part in a corporate event (like a shareholder meeting, dividend distribution, rights issue or tender offer). Think of it as a receipt that lets you vote, claim payment, or subscribe to an offering — without it, the company or regulator may not accept your participation.
Universal Registration Document regulatory
"section of the Universal Registration Document filed with the French Financial Markets Authority"
A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.
immunotherapies medical
"biotechnology company developing immunotherapies for cancer patients"
Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.
Form 6-K: How Foreign Companies Report to the SEC →



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: Thursday April 13, 2026
Commission File Number: 001-39084
Innate Pharma S.A.
(Translation of registrant's name into English)

Innate Pharma S.A.
117 Avenue de Luminy—BP 30191
13009 Marseille, France
+ 33 (0) 4 30 30 30
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]    Form 40-F [ ]


EXHIBIT INDEX

Exhibit    Description

99.1    Press Release dated April 13, 2026



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNATE PHARMA S.A.


Date: April 13, 2026    By:    /s/ JONATHAN DICKINSON     Name:    Jonathan Dickinson
Title:    Chief Executive officer



EXHIBIT 99.1

INNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON MAY 21, 2026

Marseille, France, April 13, 2026, 7:00 AM CEST

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual General Meeting of shareholders (“AGM”) at 10:30 a.m. CEST on May 21, 2026, at its headquarters, 117 avenue de Luminy, 13009 Marseille.

The notice of meeting for this AGM was published on April 13, 2026 in the French Bulletin des annonces légales obligatoires (BALO). It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this AGM.

Documents and information relating to the AGM will be made available to shareholders in compliance with current regulations on the Investors section of the Company's website.

****

The AGM will also be broadcast live and accessible at the following link:

Innate Pharma 2026 Annual General Meeting

A guided tour of the Company's laboratories will be organized on the same day at 9:15 a.m. CEST for shareholders. Shareholders can register for the tour via the following link: registration form.

****

Further information regarding the AGM:

Only shareholders who have registered their shares in an account at least five trading business days prior to the date of the AGM, i.e. May 14, 2026, at 00:00 (Paris time), will be entitled to attend the General Meeting.

Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers. This “attestation de participation” must be attached to the voting or proxy form.

Written questions from shareholders must be received no later than four business days prior to the AGM, i.e. May 15, 2026, at the following address: investors@innate-pharma.fr.

Shareholders can also obtain the documents and information relating to the AGM (as described in Article R. 225-83 of the French Commercial Code) by sending a request by e-mail to investors@innate-pharma.fr.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com. Follow us on LinkedIn and X.










Information about Innate Pharma shares

ISIN code FR0010331421
Ticker code Euronext: IPH Nasdaq: IPHA
LEI 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors

investors & Media Relations

Innate Pharma 

 Stéphanie Cornen 

stephanie.cornen@innate-pharma.fr 

Investor Relations 

investors@innate-pharma.fr 

Media 

communication@innate-pharma.fr 









Source: View Original Filing on SEC EDGAR

FAQ

When is Innate Pharma (IPHA) holding its 2026 Annual General Meeting?

Innate Pharma will hold its 2026 Annual General Meeting on May 21, 2026, at 10:30 a.m. CEST. The meeting will take place at the company’s headquarters in Marseille and will also be broadcast live online for remote access.

How can Innate Pharma (IPHA) shareholders attend and vote at the 2026 AGM?

Shareholders must have their shares registered in an account at least five trading days before the AGM, by May 14, 2026. Bearer shareholders need a broker-issued “attestation de participation” attached to their voting or proxy form to attend and vote.

Is there an online broadcast of Innate Pharma’s 2026 Annual General Meeting?

Yes, the 2026 Annual General Meeting will be broadcast live online via a dedicated link. This allows shareholders who cannot attend in person at the Marseille headquarters to follow the meeting proceedings remotely in real time.

What is the deadline for Innate Pharma (IPHA) shareholders to submit written questions for the AGM?

Written questions from shareholders must be received no later than four business days before the AGM, on May 15, 2026. Questions should be sent by email to the dedicated investor relations address provided by the company.

Will there be a lab tour for Innate Pharma shareholders on the AGM day?

Yes, a guided tour of Innate Pharma’s laboratories will be held on May 21, 2026, at 9:15 a.m. CEST. Shareholders need to register in advance using the online registration form linked in the company’s AGM communication.

Where can Innate Pharma (IPHA) shareholders find AGM documents and proposed resolutions?

AGM documents, including the agenda and proposed resolutions, are available on the Investors section of Innate Pharma’s website. They were also summarized in the notice published in the French legal bulletin BALO on April 13, 2026.

Filing Exhibits & Attachments

1 document

Press Releases